Going-concern warnings, bankruptcies, restructurings, staff cuts and sharp stock drops at public biotech companies, newest first.
Distress ·
A termination agreement ends the license and assigns the patents and know-how to Mineralys. Up to $255.0 million in commercial milestones still applies.
MLYSA supreme court building with lit columns. CC0, via rawpixel
Distress
Bristol Myers Squibb will end its PRX019 license on January 28, 2027, dropping up to $617.5 million in milestones it could have owed. The 8-K cites an internal strategic review and gives no further reason.
PRTA
Distress
The VIZZ maker targets approximately $70 million to $75 million in 2027 operating expenses, and CEO Eef Schimmelpennink will step down December 1, 2026.
LENZ
Distress
The company ended AlloNK development after two patient deaths and durability data that did not meet its threshold. It reported about $319.1 million in cash, cash equivalents and investments at September 30, 2026, a preliminary figure.
ARTV
Distress
An amended monthly operating report for the period ended July 31, 2026 shows $16,906,955 in cash and a July loss of $11,165,298. It also lists an $18 million replacement debtor-in-possession loan.
SGMOQSupernus ended its UBS credit line on October 20, 2026, with nothing drawn and no penalty. The filing says the combined company is to enter a new senior secured facility at closing, but it gives no closing date and no terms.
SUPNThe company expects quarterly cash burn to fall by about half, to roughly $8 million, and says its cash lasts into the second quarter of 2027.
GUTSLucia missed its non-inferiority goal against Eylea. EyePoint will end both wet AMD trials early and put its cash behind two diabetic macular edema studies due in late 2027.
EYPTCollegium will pay Grünenthal $17,000,000 to end a February 2026 patent suit and a Nucynta license that carried royalties. The 8-K does not say what those royalties cost the company.
COLLPatients kept about 80% of their tirzepatide weight loss after one Revita procedure versus 67% after sham. Fractyl plans a De Novo filing in late fourth quarter 2026.
GUTSThe deal ends six lawsuits. Liquidia also owes $145.4 million in two installments due in 2027 and $60.3 million to other parties this month.
LQDAUTHRThe company did not cure asserted defaults, returned two Citation CJ3 aircraft on October 1, 2026, and lessors claim approximately $514,557 under the leases.
PREMThe Berkeley CRISPR company will discontinue vispa-cel and CB-011, cut staff and hire Wedbush. It had $113.8 million in cash on June 30 and expects $15 million to $19 million in restructuring costs.
CRBUPetros Pharmaceuticals assigned all of its assets to PT Liquidation, LLC for the benefit of creditors on September 30, 2026, and says it has ceased substantially all operations. The executive chairman and two directors resigned the same day, and the Series A preferred stock must be redeemed immediately.
PTPIThe company, formerly Renovaro Inc., expects to file its Form 10-K for the year ended June 30, 2026 within the 15-day grace period. Its net loss for the prior year was about $178.0 million.
LNAIAdvanced Biomed told the SEC it could not file its annual report for the year ended June 30, 2026 on time because the audit was not finished. The notice does not name the auditor or explain the delay beyond that.
ADVBThe Form 10-KT covers the eight months ended June 30, 2026. The company expects to file within the 15-day grace period.
ZEOXThe company filed a late-filing notice for the year ended June 30, 2026. It says it has not been able to compile the financial data for its Form 10-K.
AAGHThe board opened a formal process to explore alternatives that may include an acquisition, merger or other transaction, and the company has set no timetable.
ADGMThe company stopped enrolling in its phase 3 MDD and bipolar studies of azetukalner. Fierce Biotech reported the shares fell 26% pre-market the next day.
XENESionna Therapeutics said it will cut about 46% of its workforce, expects about $6.4 million in restructuring charges, and expects its cash to last into the second half of 2029. The cuts follow a missed key endpoint for SION-719 in a Phase 2a trial.
SIONThe 121-patient trial failed at every dose. Evommune will keep testing EVO756 in migraine, move EVO301 forward and says cash lasts into 2029, a forecast that rests on revised plans.
EVMNTScan will cut about 75% of its workforce, stop enrolling its phase 3 ALLOHA-2 trial for lack of capital and focus on solid tumors. Amgen is also ending a Crohn's disease collaboration, and Nasdaq has warned that the stock failed the $1.00 minimum bid for 30 straight trading days.
TCRXAMGNTeva is the stalking horse bidder for BioXcel's dexmedetomidine film, which faces an FDA decision on at-home use by Nov. 14. Other bidders can still top the offer.
TEVABioXcel filed Chapter 11 on Aug 27 with Teva's $57.5 million upfront bid as the floor for a court auction. That upfront sum is below the company's $107,152 thousand of total debt at June 30.
BTAITEVAPTC Therapeutics will pay $111 million upfront and up to $100 million more in milestones for ST-920, subject to approval by the bankruptcy court.
PTCTPDS Biotechnology approved a reduction in force on August 6, 2026 and estimates a one-time charge of approximately $842,000. It also ended Stephan Toutain's role as Chief Operating Officer.
PDSBOutlook says it cannot file its quarterly report on time because of its size, finance department turnover and work on a public offering that closed on August 14, 2026. It has a going concern warning in its last annual report.
OTLKCuranex says its cash will not last twelve months, a reversal of the no-doubt finding in its first-quarter report. Prepaid research payments have so far held cash use well below its losses.
CURXManagement said cash would last through the fourth quarter of 2026. The company has leaned on at-the-market sales and small offerings, and a Nasdaq delisting notice followed on August 18.
SLXNNutra Pharma filed a Form 12b-25 notice on August 14, 2026, saying its quarterly report for the period ended June 30, 2026 would be late. Its cash at December 31, 2025 was $12,181.
NPHCThe notice also says its 2025 Form 10-K and its March 31, 2026 Form 10-Q have not been filed. The company cites delays in finishing its financial statements and an auditor review.
PKTXWinning bids yield about $163.55 million in cash at closing and up to $100 million in milestones. Every sale still needs court approval, and the company is still selling other assets.
SGMOQLLYThe company says its cash lasts through the first quarter of 2027 and it will need more capital after that. SOTERIA is due to start in the second half of 2026.
PLYXPelthos Therapeutics said on August 13, 2026 that its first-quarter 2026 financial statements can no longer be relied on. The restatement adds $14.8 million to the accumulated deficit, and the company reports a material weakness in its controls over convertible debt.
PTHSRegen Biopharma says a delay in its public accountant's review kept it from finishing the Form 10-Q for the period ended June 30, 2026. It says it will file within five calendar days of the due date.
RGBPPTC says the ST-920 rolling BLA will be completed in the fourth quarter of 2026, with a potential commercial launch in 2027 if the acquisition closes.
PTCTManagement says June 30 cash covers GX-03 work in atopic dermatitis into the third quarter of 2027, but the 10-Q also raises substantial doubt that Turn can continue as a going concern.
TTRXThe company is refocusing on ocular oncology and minimizing resources for its bladder cancer program. Its Phase 3 CoMpass trial is fully enrolled with 108 patients.
AURAAnavex (Nasdaq: AVXL) cannot file its 10-Q for the quarter ended June 30, 2026 on time. The company also lists its 10-Q for the quarter ended March 31, 2026 as not yet filed.
AVXLThe company cites a special committee's review of matters tied to the April 30, 2026 termination of its chief executive. Its quarterly report for the period ended March 31, 2026 is also listed as not filed.
AVXLA $191.3 million non-cash impairment charge drove the loss. The company expects annualized savings of approximately $40 million from the restructuring.
EBSBio-Rad Laboratories said on August 4, 2026 that the plan includes position eliminations and facility closures worldwide and is expected to be substantially completed by the end of fiscal year 2027. Second-quarter net sales were $651.0 million.
BIOKuva Labs could not raise the money to complete its $4.00 tender offer for Lisata. Lisata then cut about 72% of its staff, and on Sept 17 it bought Marea with a $225 million private placement that heavily dilutes existing holders.
LSTACash and short-term investments were $690.7 million at June 30. The company sold $230.8 million of stock in the second quarter through its ATM.
SMMTThe amended agreement sets a maximum price of $21,306,000 for companies bought from seller Gary C. Bernard, M.D., and it depends on a related business combination that has not closed.
FCHSArbutus said it expects to begin returning up to about $230 million to shareholders in Q3 2026, but the form is not set, the board must approve it, and repurchases cannot start until a dividend from Genevant's parent arrives. The company received about $178 million from Moderna on July 8, 2026.
ABUSROIVThe $4,000,000.00 PNC line now runs to April 14, 2027, and a new Convertible ELOC of up to $250,000.00 replaces a matured $500,000.00 equipment note.
INBPBoundless Bio agreed to an all-stock merger with privately held Serapha Bio and said it would cut about 75% of its workforce. After closing, Boundless holders would own about 3.69% of the combined company, and most of the early data behind the deal come from a trial in Shanghai.
BOLDSL Science Holding completed its merger with Horizon Space Acquisition II on June 12, 2026. Its shell company report says its three product candidates are still in preclinical testing, and that its financial statements carry a going-concern warning.
SLBTPolomar and Altanine terminated their merger agreement as of June 12, 2026, and ended a related patent license. Polomar has until September 7, 2026, to sell remaining inventory under that license.
PMHSNeumora Therapeutics is ending development of navacaprant after its two Phase 3 KOASTAL trials in major depressive disorder missed statistical significance. It cut about 35% of its workforce and amended a loan with K2 HealthVentures, and it says its cash will last into the third quarter of 2027.
NMRAenGene Therapeutics is cutting about 50% of its workforce and expects restructuring costs of $5.7 million to $6.4 million. It reported $285.2 million of cash at April 30, 2026, while its key trial data are interim and its FDA path depends on durability data not yet in hand.
ENGNThe bladder cancer gene therapy developer stopped enrollment in three study cohorts to conserve cash. It plans to start its BLA filing in the second half of 2026.
ENGNA bankruptcy court approved the sale of substantially all of Lipella's assets to XRAIY LLC under an agreement dated May 14, 2026, in a chapter 11 case filed on March 30, 2026.
LIPOThe restructuring follows the discontinuation of pociredir for sickle cell disease and carries expected charges of approximately $4.2 million. Leerink Partners LLC is advising the board.
FULCFulcrum ends pociredir, its lead sickle cell program, after FDA concerns about malignancy risk, and sets no timeline for its strategic review. It reported $333.3 million in cash, cash equivalents and marketable securities as of March 31, 2026.
FULCFifth Third Bank's May 29, 2026 notice cites four specified events of default under the credit agreement and raises the interest rate to the default rate.
AMSAkari Therapeutics says its quarterly report for the period ended March 31, 2026 will be late, partly because of work on an upcoming public offering. It also expects a material non-cash impairment charge, and its March 2026 annual report carried a going-concern paragraph.
AKTXA May 11, 2026 consent and waiver letter sets aside several closing conditions and requires updated audited financial statements. A May 12 amendment cuts the chief executive's base salary to $19,000 a month.
PMHSApimeds (APUS) says it needs more time to finalize financial statements for the quarter ended March 31, 2026 and expects to file within a five-calendar-day extension. Its latest 10-K carries a going concern paragraph.
APUSExicure says it needs more time to finish its quarterly report and expects a net loss of approximately $1,827,911 for the quarter. Cash fell to about $2,504,054 by March 31, 2026, and its 10-K already carried a going-concern warning.
XCUROramed Pharmaceuticals says it needs more time to finish the financial statements for the quarter ended March 31, 2026, and expects to file within five calendar days of the due date. Its 2025 annual report showed a $7,675,000 Scilex note due March 31, 2026, and going-concern warnings at two companies it has invested in.
ORMPScilex Holding Company says it needs more time to finish its first-quarter 2026 financial statements, including the consolidation of Vivasor Holding Company, and expects to file by May 20, 2026. Its 2025 annual report carries a going-concern warning and an accumulated deficit of about $921.8 million.
SCLXOS Therapies will miss the May 15, 2026 deadline for its first-quarter 10-Q and says it expects to file within the five-day extension. The filing comes from a company whose annual report, filed March 31, 2026, carries a going-concern warning and reports $269,830 of cash at year-end.
OSTXABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period.
ABVCCell Source, an OTC Pink company, signed a 10-Q on May 14, 2026 for the quarter ended March 31, 2025. It reports $1,240 of cash, a going-concern warning, and notes past due, while it prepares a Nasdaq uplisting.
CLCSAnavex Life Sciences told the SEC on May 11, 2026 that it cannot file its first-quarter 10-Q on time. The delay follows the April 30 termination of CEO Christopher Missling, and the company says the review of that termination may take longer than it expects.
AVXLOperating expenses fell to $31.0 million from $46.2 million, but revenue fell by $27.3 million and the net loss was approximately $27.0 million.
ARCTAddex Therapeutics filed a Form NT 20-F on April 30, 2026, saying it will miss the deadline for its 2025 annual report. It reported a 2025 net loss of CHF 6.7 million, against a 2024 profit of CHF 7.1 million that the company ties to a sale of part of its business.
ADXNThe company says compiling and reviewing the information has imposed time constraints. It undertakes to file no later than 15 days after the original due date.
TLSAThe company says it lacks operational and financial data for its subsidiary The Social Proxy Ltd., which is in liquidation proceedings.
XTLBAutolus will cut about 13% of its workforce and expects about $8 million in severance and related charges, with savings of about $15 million a year from 2027. It reiterated 2026 AUCATZYL revenue guidance of $120 million to $135 million, while its 10-K reports a 2025 net loss of $287.5 million and cash used in operations of $283.6 million.
AUTLThe company expects about $8 million in restructuring charges and continues to expect its cash to fund operations into the fourth quarter of 2027.
AUTLThe company says it needs more time to finalize its audited financial statements and expects to file within 15 calendar days of the due date.
MENSCASI Pharmaceuticals filed a Form NT 20-F on April 21, 2026, saying its annual report on Form 20-F for 2025 will be late because its U.S. GAAP financial statements are not yet available. It expects that report to say there remains substantial doubt about its ability to continue as a going concern.
CASIFEli Lilly gave notice on April 16, 2026 that it is terminating its license for ocadusertib, a RIPK1 inhibitor, effective June 15, 2026. Rigel expects to regain full rights and does not expect future milestones or royalties under the agreement.
RIGLSemnur ended a private placement agreement with JW Capital Securities Limited and a share purchase agreement with Biconomy PTE. Ltd. Neither agreement had produced any issued shares.
SMNRThe Fourth Amendment, dated April 10, 2026, makes the notes payable in full at the earliest of three events. It bars prepayment for six months without Adjuvant's consent.
EVFMThe company says it needs more time to complete its 2025 annual report because of reduced headcount and negative Phase 3 results. It expects to file within the fifteen calendar day extension under Rule 12b-25.
IRLAScilex Holding Company says it could not file its annual report by the March 31, 2026 due date and expects to file by April 15, 2026. It says it needs more time to finalize financial statements, including consolidating Vivasor Holding Company.
SCLXChina Pharma says it will file its 2025 annual report within fifteen calendar days after March 31, 2026. Its estimates show revenue of $4.1 million and a net loss of about $3.19 million, and its auditors have raised going-concern doubt before.
CPHITherapeuticsMD filed a Form 12b-25 notice on April 1, 2026 after a printer error left the predecessor auditor's report out of its 2025 annual report. The company reported a 2025 net loss of $569,000 and year-end cash of $7.5 million.
TXMDGreenwich LifeSciences said on March 31, 2026 that its annual report for 2025 would be late. Its 2024 annual report already carried an auditor's going concern paragraph, with $4,091,990 in cash at year end against a $15,788,809 net loss.
GLSIGeoVax missed the March 31, 2026 deadline for its 2025 annual report and expects to file within 15 days. It expects a 2025 net loss of about $21.5 million, and its 2024 annual report carried a going-concern warning from the auditors.
GOVXTraws Pharma filed a Form NT 10-K on March 31, 2026, saying it has not yet signed any financing and needs time to assess how a deal would affect its going-concern evaluation. The notice also gives unaudited 2025 net income of about $9.2 million, driven by a $26.7 million warrant accounting gain.
TRAWSunshine Biopharma filed a Form 12b-25 on March 31, 2026 for its 10-K for the year ended December 31, 2025. It cites time constraints and says it will file no later than fifteen days after the original due date. Its 2024 net loss was $5,134,116.
SBFMTransCode blames the complexity of accounting for its October 2025 deal with DEFJ, LLC, including a roughly $25 million Series B preferred placement. It expects to file within the extension period.
RNAZThe company cites issues tied to its Advent BioServices acquisition, including differences between UK GAAP and US GAAP. The notice gives no date for the annual report.
NWBOThe deal settles a Delaware lawsuit. Zevra says it repaid its $63 million term loan in full before signing.
ZVRAGenentech elected to terminate the agreement for convenience. Xencor says it expected the move.
XNCRInMed's board approved exiting BayMedica's sales on March 4, 2026. The company calls BayMedica its only revenue-generating business, expects about $550,000 in severance costs and about $120,000 in other spending, and its annual report already carries a going-concern warning.
INMOn March 1, 2026 the audit committee concluded the quarterly reports contained an error: Greenshoe Rights from a May 2025 private placement required liability classification. GT Biopharma (Nasdaq: GTBP) will file Forms 10-Q/A.
GTBPThe February 25, 2026 termination involves no payments. Acrivon keeps full rights to its ACR-368 OncoSignature test.
ACRVThe audit report says XORTX must finance its research or postpone it. The statements show an accumulated deficit of $23,824,557 at December 31, 2025.
XRTXAfter an enterprise-wide strategic review, Viatris committed to restructuring that it expects to cut its global workforce by up to approximately 10%. It expects potential savings of between $600 million and $700 million.
VTRSThe company lowered its expected cell therapy restructuring cash costs to €125 to €175 million. It expects to be a lean organization of about 35-40 employees by the end of 2026.
LKFTWerewolf expects a one-time charge of approximately $4.1 million in the first quarter of 2026. The filing also discloses the company's efforts to raise capital and a review of strategic partnerships for WTX-124 and WTX-330.
HOWLThe senior secured facility matures February 1, 2031. Maze ended its Banc of California loan agreement in connection with the deal.
MAZEUMeWorld filed a notice on February 2, 2026 that its quarterly report for the quarter ended December 31, 2025 will be late. Its auditor, J&S Associate PLT, resigned on December 31, 2025, and the company has not yet engaged a successor, so the review of its interim results has not started.
UMEWBGM Group Ltd. says it cannot file its annual report on Form 20-F for the year ended September 30, 2025 on time. It is still finishing the consolidation and acquisition accounting for its purchase of YX Management Company Limited.
BGMGeron Corporation estimates about $18 million in restructuring charges, mostly severance and benefits, and expects the workforce reduction to be substantially complete in the first quarter of 2026.
GERNThe company estimates about $18 million in restructuring charges, mostly severance and benefits, hitting results in the fourth quarter of 2025 and the first quarter of 2026.
GERNPharmaCyte Biotech will miss the December 15, 2025 deadline for its quarterly report and says it will file within five calendar days. The company's latest annual report says its licensed patents have expired and that the know-how for its core technology sits with a partner, while it has cut program spending during a board review.
PMCBCullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026.
CGEMAdvanced Biomed, which carried a going-concern warning and a Nasdaq bid price notice in its last annual report, says the review of its September 30, 2025 quarter is not finished.
ADVBQ/C Technologies told the SEC on November 14, 2025 that it needs more time to finalize its quarterly report for the nine months ended September 30, 2025. The company filed its April 2025 annual report under the name TNF Pharmaceuticals, and that report carried a going-concern warning.
QCLSKorro Bio cut about 34% of its workforce on November 12, 2025, paused its Novo Nordisk collaboration for 12 months, and said the moves extend its cash into the second half of 2027. Its chief medical officer also resigned, and its lead RNA editing candidate fell short of the protein levels the company had projected.
KRROArcturus blamed a technical transmission error for missing the deadline on its September 30, 2025 quarterly report. The notice gives no results, and the company's 2024 annual report shows cash use rising sharply.
ARCTArcturus says a technical transmission error caused it to miss the 5:30 PM Eastern deadline on November 10, 2025 for its quarterly report. Its commercial product is KOSTAIVE, a COVID-19 vaccine sold in Japan.
ARCTThe RNA editing company ended the third quarter of 2025 with $102.5 million in cash and securities. Its AATD drug candidate KRRO-110 did not reach projected protein levels.
KRROTScan expects annual cost savings of $45.0 million in 2026 and 2027 and a one-time charge of up to approximately $2.3 million. It says its cash runway now extends into the second half of 2027.
TCRXThe company expects to file its annual report for the year ended June 30, 2025 within the fifteen-day grace period.
GELSThe company expects to file its annual report for the year ended June 30, 2025 no later than the fifteenth calendar day after the due date.
KZIAAlector expects $7.7 million in restructuring charges and reports a preliminary $291.1 million in cash and short-term investments at September 30, 2025. Its head of research and development is resigning.
ALECBolt will cut about 20 employees, roughly 50% of its workforce, with pre-tax charges of $1.5 million to $2.0 million. The company says the cut extends its cash runway into 2027. Initial BDC-4182 clinical data, now expected in the third quarter of 2026, will come later after a protocol change.
BOLTTheriva says cutting about seven employees, or 32% of its global workforce, and other cost cuts extend its cash runway into the second quarter of 2026. Its 2024 annual report carried a going-concern warning, and the company reported $11.6 million of cash and equivalents at December 31, 2024.
TOVXOxford Finance says an event of default under a Material Adverse Change clause is continuing and has accelerated all obligations under the 2021 loan agreement. The notice says interest began accruing at the Default Rate, and that $29.1 million is now payable.
KALAKALA BIO will stop developing KPI-012 and its stem cell secretome platform, cut approximately 19 employees and talk with its secured lender while it explores strategic options.
KALASutro Biopharma (Nasdaq: STRO) plans a workforce reduction of approximately one-third to focus on three preclinical ADC programs. It estimates $4.1 million to $4.3 million in costs.
STROArvinas said on September 17, 2025 that it will cut its workforce by a further 15%, mainly in vepdegestrant commercialization roles, and that it will seek a third party to take over the drug with Pfizer. The same day its board authorized a buyback of up to $100 million, and the filing does not give the cash balance on which that depends.
ARVNX4 is cutting about 50% of its workforce for annualized savings of about $13 million, with cash charges of about $3.3 million, after three executives were terminated and its chief medical officer resigned. Its 2024 annual report carried a going-concern warning tied to a loan covenant with Hercules.
XFORThe company and Pfizer have agreed to out-license vepdegestrant commercialization rights and have begun looking for a partner. Arvinas expects about $4.5 million in workforce costs.
ARVNBenitec's Audit Committee found share-based compensation expense was understated in the quarters ended December 31, 2024 and March 31, 2025. The company expects to file its 2025 annual report on time.
BNTCAbivax reported a first-half net loss of EUR 100.8 million and negative shareholders' equity of EUR 48.3 million at June 30, 2025, before a July US offering and several note conversions. The company now says its cash lasts into the fourth quarter of 2027.
ABVXThe company is focusing on its late-stage active immunotherapy programs and two small molecule programs. It says near-term clinical milestones are unchanged.
ACIUIndivior says its Action Agenda initiative brings headcount reductions and real estate consolidations. It expects $27 million to $35 million of the charges to be cash and is exploring strategic alternatives for OPVEE and its non-U.S. business.
INDVEvogene is cutting 30% of its workforce and says an $18.71 million asset sale and a $4.4 million share program give it an 18-month runway. The $11.7 million cash figure leaves out the sale proceeds, and the company's equity attributable to shareholders is negative.
EVGNThe company says it needs more time to review its financial statements after recent changes in management. It expects to file its Form 10-Q within the five calendar day period under Rule 12b-25.
CINGOS Therapies could not file its quarterly report for the period ended June 30, 2025 by its August 14, 2025 due date. Its last annual report carried an auditor's going concern warning and showed $5,533,527 of cash at the end of 2024.
OSTXAgentix has no meaningful revenue, and its lead drug candidate has animal efficacy data only in its annual report. It says it cannot finish its quarterly report on time and expects to file by August 19, 2025.
AGTXThe company needs more time to value marketable securities it received as part payment for Series D Preferred Stock. It estimates an $18.5 million net loss for the quarter and a $33.4 million loss attributable to common shareholders.
CEROCingulate filed a late-filing notice for its report on the quarter ended June 30, 2025. It expects to file within the five-day extension period.
CINGCosmos Health said it could not finish its June 30, 2025 Form 10-Q on time, blaming delays in obtaining and compiling information, including its XBRL filing. It does not expect a significant change in results from a year earlier.
COSMHCW Biologics says it needs more time to finish its June quarter 10-Q and expects to file within the five-day grace period. The notice gives no revenue, loss or cash figures.
HCWBThe company said its financial statements could not be completed in time for review and signatures. It checked the box saying it will file within the grace period.
LIMNOS Therapies says it needs more time to finish its financial statement close for the quarter ended June 30, 2025, and expects to file within the five-day extension.
OSTXSigyn Therapeutics filed a Form 12b-25 notice on August 15, 2025 saying it cannot file its quarterly report for the period ended June 30, 2025 on time. It promises to file no later than five days after the original due date.
SIGYThe company says $0.4 million of milestone payments to Sarborg Limited were booked as research and development expense but should have been an acquired diagnostic asset. It plans to amend its first-quarter Form 10-Q.
CDTAllarity says its auditors have not finished reviewing the quarter. It expects to file within five calendar days of the due date and does not anticipate a significant change in results from a year earlier.
ALLRNRx Pharmaceuticals (Nasdaq: NRXP) told the SEC it needs more time to compile information for its June 30, 2025 quarterly report. It expects to file within five calendar days of the due date.
NRXPThe company filed a late-filing notice on August 14, 2025 for its report on the quarter ended June 30, 2025. It expects to file within the extension period, but its auditors had not finished their review.
ALLRApimeds says it cannot file its quarterly report for the period ended June 30, 2025 on time and expects to file within the five-day extension. Its lead drug, Apitox, rests on a prior Phase III trial that the company's own filing describes in conflicting terms.
APUSThe company also has not filed its annual reports for 2023 and 2024. It expects to disclose substantial doubt about its ability to continue as a going concern.
ELOXGoldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has not been filed, and its latest filed balance sheet is small.
GWLLJupiter said it needs more time to complete the presentation and review of its financial statements. It expects to file within five calendar days of the deadline and says it anticipates no significant change in results.
JUNSNRx told the SEC it will miss the regular deadline for its June quarter report and needs more time to compile information. It expects to file within the form's five-day grace period, and the notice gives no figures.
NRXPNeOnc needs more time to review non-cash expense charges tied to previously granted restricted stock units. It expects to file within five days.
NTHIThe company said it is working with its auditor to finish the review of its Form 10-Q. It expects to file within 5 calendar days of the due date.
OCEAProtagenic Therapeutics said on August 14, 2025 that it cannot file its June quarter report on time, because its board approved a restructuring to a virtual operating model on August 8. The company expects to file by August 19, 2025, and the notice gives no cost or cash estimate for the restructuring.
PTIXTNF Pharmaceuticals says it needs more time to finish the financial statements for the six months ended June 30, 2025, and expects to file within the extension window. The notice does not say what is holding up the numbers.
QCLSDenali Capital filed a Form 12b-25 notice on August 14, 2025 saying it cannot file its June 30, 2025 quarterly report on time, because it is still completing its financial statements. The notice says the report will come no later than the fifth calendar day after the due date.
SMNRThe company said it needs more time to finalize its financial statements and related disclosures. It expects to file within five calendar days after the due date.
WINTORIC expects a one-time cost of approximately $1.9 million for the workforce reduction. The company says cash and investments should fund its revised operating plan into 2H 2028, helped by $244 million in gross proceeds.
ORICFate Therapeutics (Nasdaq: FATE) expects $0.9 million to $1.2 million in severance charges in the third quarter of 2025. The company says it has $249 million in cash and investments and a runway through the end of 2027.
FATEMosaic ImmunoEngineering missed the 5:30 p.m. EDT August 14, 2025 deadline for its second-quarter report, citing financial reporting and close procedures. Its annual report warned it might have to cease operations if a deal with Oncotelic and note-holder waivers were not secured by June 30, 2025.
CPMVThe company ended discovery research to focus on ORIC-944 and enozertinib. It does not expect to use its at-the-market facility for the foreseeable future.
ORICMerck expects to eliminate certain positions in sales, administrative and research and development organizations and expects annual savings of approximately $1.7 billion, substantially realized by the end of 2027.
MRKThe company said it needs more time to prepare and review its financial statements. It plans to file within 15 days of the July 29, 2025 due date.
PMCBRocket says the plan, approved by its board on June 18, 2025, aims to extend its operational runway into the second quarter of 2027. The company expects about $3.5 million in charges in the second half of 2025, against a 2024 operating cash outflow of $209.7 million.
RCKTAdicet's board approved a cut of about 30% of its workforce on July 22, 2025 and ended its ADI-270 cancer program. The company expects about $2.3 million in charges and a cash runway into the fourth quarter of 2026, after a $117.1 million net loss in 2024.
ACETMaloneBailey said recurring losses and a net capital deficiency raise substantial doubt. Stockholders' equity fell to $2,857 thousand from $11,752 thousand.
ARTLPacira is shutting down its 45-liter EXPAREL suite in San Diego and cutting 71 employees, about 8% of its workforce. It expects $2.4 million to $2.8 million of cash charges in the third quarter and about $13 million a year in lower operating expenses.
PCRXPacira is closing its 45-liter EXPAREL manufacturing system and cutting about 70 Technical Operations jobs, and the employee note it filed says the larger 200-liter process in San Diego and Swindon now supplies the product.
PCRXJasper's board approved a corporate reorganization on July 8, 2025. The company will focus on briquilimab in chronic urticaria, expects $1.8 million to $2.2 million in severance cash costs, and its chief medical officer is leaving.
JSPRCentury Therapeutics (Nasdaq: IPSC) expects to cut headcount by approximately 51% and record about $3.7 million in severance charges. Its CFO and Chief Development Officer will leave in July 2025.
IPSCPacira signed a $300.0 million senior secured revolving credit facility with Wells Fargo as administrative agent, and used part of it to repay its 2023 term loan A. The filing does not say how much was drawn.
PCRXAmarin will receive $25 million upfront and up to $150 million in milestones under a 59-country license. It also expects a global restructuring to cut operating costs by approximately $70 million annually.
AMRNAmarin is licensing Vazkepa in Europe to Recordati for a $25 million upfront payment and starting a restructuring that targets about $70 million in cost savings over the next 12 months, while the release gives no loss or cash-flow figures.
AMRNProthena expects $16 to $20 million in severance and related charges from the workforce reduction. Its Chief Regulatory Officer and Chief People Officer will leave effective August 1, 2025.
PRTAProthena will cut about 63% of its workforce after ending birtamimab, and expects $16 to $20 million in charges, mostly cash. The 8-K gives no headcount, cash balance or savings figure.
PRTAADC Therapeutics approved a restructuring on June 11, 2025 that closes its U.K. research facility and cuts about 30% of its global workforce. The same day it agreed to a $100 million private placement priced at $3.53 per share.
ADCTRelay paid a lease modification payment of approximately $2.5 million and a relocation payment of approximately $3.5 million. It says the changes cut rent expense by approximately $16 million.
RLAYActuate Therapeutics filed a corporate overview dated May 31, 2025 that repeats its going-concern warning and says it needs capital to fund operations beyond the second quarter of fiscal 2025. The deck's survival figures are draft, unaudited data, and its progression-free survival result is not statistically significant.
ACTUAdlai Nortye's Phase III BURAN trial of buparlisib missed its overall survival endpoint, the company is dropping the drug, and it plans to cut staff "to preserve cash," with the release giving no survival figures.
ANLKeros's board approved a plan on May 28, 2025 to cut its overall workforce by about 45%, with about $3.2 million in severance charges and up to about $0.4 million in retention costs. The cuts follow the January 2025 early termination of the PAH trial over pericardial effusion events, though the company held $559.9 million in cash at the end of 2024.
KROSHeadcount will fall to 85 full-time employees, with average annualized savings of about $17 million. The strategic alternatives review is still under way.
KROSBoundless Bio will drop current BBI-355 trial arms and test BBI-355 with BBI-825. The cut is expected to cost about $1.2 million. Cash and short-term investments were $138.3 million on March 31, 2025, with runway expected into the first half of 2028.
BOLDThe company says it needs more time to compile its financial statements for the quarter ended March 31, 2025, including to reflect the May 9, 2025 reverse stock split.
HINDExicure told the SEC on May 15, 2025 that it cannot file its quarterly report for the period ended March 31, 2025 on time, because it has not finished the accounting for its acquisition of GPCR Therapeutics USA, Inc. The company expects to file within the five-day extension that Rule 12b-25 allows, and it says the acquisition will make the quarter's results hard to compare with last year.
XCUREloxx says it cannot afford to engage its auditor to review first quarter 2025 financials, and it expects to disclose substantial doubt about its ability to continue as a going concern. It expects cash of $0.4 million at March 31, 2025.
ELOXThe company filed an NT 10-Q on May 15, 2025. It needs more time to account for warrants from a March 2025 private placement and expects lower stockholders' equity at March 31, 2025.
CNSYAspira says it needs more time to finish accounting for debt and equity deals from the first quarter, and it expects a smaller net loss helped by a milestone payment.
AWHLThe company needs more time to finalize accounting for common stock purchase warrants issued in its March 2025 private placement. It expects a warrant liability that will lower stockholders' equity.
CNSYThe company filed a late-filing notice for its quarterly report for the three months ended March 31, 2025. Its lead candidate, GLSI-100, is in a Phase III trial that is still expanding.
GLSIHepion says it is still compiling information for its March quarter 10-Q and expects to file within five calendar days. The notice previews research and development spending of $22,235, down from $2.5 million.
HEPAReShape says a reverse stock split on May 9, 2025 is one reason its March quarter 10-Q needs more time. It expects to file within the five-day extension and says it does not expect a significant change in results.
HINDNeuphoria said it needs more time to compile supporting documents and let its auditor finish its review. It expects to file within the five-day extension period.
NEUPNovelStem says its auditors need more time to finish their review of the March quarter, and it expects to file within five calendar days after the due date. NewStem, in which it holds about 31%, ceased operations and began liquidation in October 2024.
NSTMThe company blamed a delay in finalizing its statements with its auditors after its February 14, 2025 business combination.
OSRHThe company said it needs more time on the purchase price allocation for GPCR Therapeutics USA, Inc. It expects results to change significantly from the March 31, 2024 quarter.
XCURCitius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price.
CTORCTXRThe company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31.
CTXRCTORThe company will keep about 23 employees after the cut and expects about $1.4 million in severance. Its latest annual report said cash of $42.5 million would not last twelve months and that about $15 million more was needed to pursue US approval of its lead drug.
ATRAVor estimates about $19.3 million in wind-down costs and plans to keep about 8 employees. Its chief financial officer and chief scientific officer were terminated without cause.
VORThe auditor's report cites recurring losses. Management also changed how it accounts for two amendments to a $100.0 million royalty-backed financing.
LQDAKorro Bio began a restructuring on May 7, 2025, cutting about 20% of its workforce and taking one-time charges of about $1.2 million. The company cut costs before its first interim data readout, and its net loss widened in the first quarter.
KRROArvinas expects about $10 million in severance and termination costs, mostly in the second quarter of 2025. It and Pfizer removed two planned Phase 3 combination trials from the joint development plan.
ARVNPliant expects to substantially complete the reduction by the end of the second quarter of 2025, with about $3.6 million in severance and related benefits. The cut follows the discontinuation of its BEACON-IPF Phase 2b trial of bexotegrast.
PLRXAN2 Therapeutics says the Phase 3 portion of its EBO-301 study missed its primary endpoint, and it projects $78.5 million in cash lasting into 2028 while it shifts to Chagas, melioidosis and oncology programs that have no human efficacy data yet.
ANTXThe company says it is still compiling required information for its annual report for the year ended December 31, 2024.
NYMXFThe company says it needs more time for financial reporting, closing procedures and other disclosure items.
XRTXThe annual report for 2024 also lists dilution risk and the availability of capital for working capital needs.
XTLBThe board approved a strategic plan on April 29, 2025 that expects about $2 million in charges, mostly severance. The company says its cash runway still reaches into the second quarter of 2027.
TRDAPfizer expects approximately $1.6 billion in one-time costs to deliver the added savings by the end of 2027. It now targets approximately $5.7 billion of total net cost savings from the program.
PFEThe company cites the conversion of its European Investment Bank debt to preferred equity and personnel losses after year-end, and expects to file by May 15, 2025.
SCNIEntrada Therapeutics will cut about 20% of its workforce, with charges of about $2 million mostly in the second quarter of 2025. The 8-K gives the cash runway as lasting into the second quarter of 2027 in one place and into the second half of 2027 in another.
TRDAThe company says it is still compiling information for its annual report for the year ended December 31, 2024.
ZYBTCaribou will reduce its workforce by 47 employees, discontinue its lupus trial, a CB-012 trial and preclinical research, and focus on CB-010 and CB-011. It reported a preliminary $212.5 million in cash and securities at March 31, 2025.
CRBUTempest Therapeutics will cut 21 of its 26 full-time employees as it explores strategic alternatives, with cuts effective April 30, 2025. It expects about $1.5 million in cash costs, mostly severance, and its 2024 10-K said cash of $30.3 million would last at least 12 months.
TPSTThe Radoff-JEC Group withdrew its director slate under the agreement. Atea's review of strategic alternatives with Evercore is still going.
AVIRCOYAThe Singapore-based company says it needs more time to finalize the report and plans to file within the fifteen-day grace period.
CUPRThe company found it had understated liabilities under one of its license agreements and expects a $3.3 million increase in each affected period. Statements for three earlier periods should no longer be relied upon.
ABPOMeiraGTx will pay base rent of $111.00 per square foot a year on a new 14,235 square foot lab at 450 East 29th Street, and it moved to end its current sublease at the same address earlier than scheduled. The 8-K does not say what the total commitment will cost.
MGTXOnconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities.
ONCOReShape Lifesciences filed a Form NT 10-K on April 1, 2025, saying it needs more time to compile information for its 2024 annual report. The notice does not explain the delay, and the company's 2023 annual report set a cost reduction target of about 55.4% for 2024.
HINDLyell expects $3.0 million to $4.0 million in closure and severance costs and net cash use of $175 million - $185 million in 2025. Its Chief Business Officer is also resigning.
LYELThe late filing covers the year ended December 31, 2024. Eloxx expects cash and cash equivalents of $0.1 million at year end and lists four periodic reports it has not filed.
ELOXThe company says it needs more time to prepare its financial statements and expects to file within the fifteen-day extension period.
ABPOThe company needs more time for the first audit by an accounting firm it retained in September 2024. It estimates a loss from operations of about $1.9 million for 2024.
EMMAThe company says it needs more time on its 2024 financial statements and audit procedures. Its lead drug, REQORSA, has a Phase 2a trial whose enrollment rules changed twice in 2024 and 2025.
GNPXEntero says it is reviewing the accounting treatment of a significant transaction and needs more time for its 2024 annual report. The business section describes an ImmunogenX rescission that the company expects to close by June 30, 2025.
GRDXThe company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023.
ONCOTevogen said a change in outside accounting providers in September 2024 left it needing more time. It will keep reporting material weaknesses in internal controls.
TVGNThe company cited delays in completing its financial statements. It expects to file within the extension period of up to fifteen calendar days under Rule 12b-25.
VCNXThe company says it is still completing its audit for the year ended December 31, 2024 and expects to file the 10-K within 15 calendar days of the due date. It does not expect a significant change in results.
ABVCThe company says it cannot file its 2024 annual report on time and expects to use the 15-day extension. Research and development expenses rose to $12,952,029, and the Phase IIb data behind its lead trial carry unresolved record gaps.
GLSIMatinas said it needs more time to review its financial statements for the year ended December 31, 2024 and plans to file its Form 10-K within the fifteen calendar day extension. It does not anticipate a significant change in results of operations.
MTNBThe company says it needs additional time to complete its financial statements for the period ended December 31, 2024. It checked the box for filing within the fifteenth calendar day after the due date.
SBFMRenovoRx (Nasdaq: RNXT) filed a late-filing notice for its 2024 annual report, citing technical accounting work with its current and former auditors. It expects to file within the 15-day grace period.
RNXTAspire Biopharma told the SEC on March 31, 2025 that it needs more time to finish its 2024 financial statements. The notice gives no reason beyond that, and its narrative refers to a 10-Q deadline that does not match the annual report it is about.
ASBPRein Therapeutics, formerly Aileron, filed a late-filing notice for its 2024 annual report and expects an impairment loss of about $37.0 million tied to a delay in developing LTI-01. The charge is non-cash, but the company's 2023 annual report already carried a going-concern warning.
RNTXABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period.
ABVCThe company is still finishing the accounting for its November 14, 2024 business combination. It expects to file within the 15-day extension.
AKTXThe company said it could not file by April 15, 2025, the original due date, because it needs more time for its financial statements.
ASBPCyclacel filed the notice on March 31, 2025, saying it needed more time to gather information. It expects to file within fifteen calendar days.
BGMSThe company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period.
BIXTCelularity expects 2024 revenue of $54.2 million and a loss from operations of $37.3 million, figures it says are still under review.
CELUDBV said talks on financing for its Viaskin Peanut program diverted management time. It plans to file the 10-K within the 15-day extension period.
DBVThe company needs more time to complete the review of its financial statements and plans to file within the fifteen calendar day extension.
MTNBThe company said it was unable to compile the financial information needed for a complete filing. It does not expect a significant change in results from the prior year.
OTLCTransCode said it needs time to account for a registered direct offering that closed on March 25, 2025. It expects to file within the Rule 12b-25 extension period.
RNAZThe impairment follows a temporary delay of further clinical work on LTI-01. The company, formerly Aileron Therapeutics, needs more time to finish its impairment assessment.
RNTXRenovoRx said it needs to complete technical accounting requirements with its current and former auditing firms. It expects to file within the fifteen-day grace period.
RNXTThe company said it needs more time to finalize its financial statements and audit. It plans to file within the fifteen-day extension.
RVPHThe Fort Lauderdale company said it needs more time to complete its financial statements. It does not expect a significant change in results.
SBFMThe company said it could not compile all the information for its financial statements in time. It expects to file within the fifteen-day grace period.
SKVISpruce expects cash to be insufficient to fund research and development for at least 12 months without new financing. It expects collaboration revenue to fall about 50%.
SPRBSavara told Evercore it is ending a $100.0 million at-the-market sales agreement, effective April 2, 2025. The company says it owes no termination penalty and has sold no shares under the agreement since December 31, 2024.
SVRATriSalus says it cannot file its 2024 annual report on time after finding errors in stock-based compensation and clinical trial expenses. It expects to file by the fifteenth calendar day after the due date. Preliminary 2024 revenue was $29.4 million.
TLSIThe company says it is still compiling information for the report. It expects to file no later than the fifteenth calendar day after the due date.
CLCSThe company expects to file within the 15-day extension period after its accounting staff finalizes the statements.
KAPAThe company found errors in the timing of stock-based compensation and clinical trial expenses. It expects to file its annual report within fifteen calendar days of the due date.
TLSINkarta is cutting 53 positions, about 34% of its staff, at an expected cost of $5.5 million to $6.5 million. It says its $380.5 million of cash and investments can fund operations into 2029, while the first clinical data from its lead program are not due until the second half of 2025.
NKTXNkarta is cutting 34% of its workforce and freezing some hires, and it says $380.5 million in cash will fund operations into 2029. Its release reports no efficacy data for NKX019, and the trials enroll small groups.
NKTXHarrow says it needs more time for accounting analyses and its internal controls evaluation. It expects no changes to preliminary 2024 results, including revenues of between $198 million and $200 million.
HROWSutro will deprioritize luvelta, exit its manufacturing facility and cut about 50% of staff, with costs of $40 million to $45 million. Jane Chung succeeds William J. Newell as CEO. Cash was $316.9 million at year-end.
STROThe blank-check company's annual report says it must liquidate if it does not close its deal with BridgeBio Oncology by February 14, 2026, and that doubt over its ability to continue is substantial.
BBOTThe company says the cut affects about 25 employees and will cost about $2.4 million. It still says cash lasts through 2026, while its lead frontotemporal dementia trial has yet to report and its term loan is secured on substantially all assets.
ALECALX Oncology's board approved a cut of about 30% of staff on Feb 28, 2025, and eliminates its president and chief scientific officer role. The company estimates about $2.2 million in severance and benefits for a lead drug that has not completed a pivotal trial.
ALXOADMA Biologics said on March 3, 2025 that KPMG LLP has not finished its audit of 2024 and expects to file the annual report by March 18, 2025. The notice attaches unaudited 2024 net income of 197,673 thousand dollars, against a 2023 net loss of 28,239 thousand dollars.
ADMAIronwood said it expects its internal control over financial reporting to be ineffective as of December 31, 2024. It plans to file within the 15-day grace period.
IRWDKiniksa has incurred about $19 million in expenses from ending the Sjögren's trial and expects $14 million to $17 million more. It reported $243.6 million in cash, cash equivalents and short-term investments and no debt, and its 2024 net loss was $43.2 million.
KNSAXencor's audit committee concluded that a 2023 royalty deal with OMERS Life Sciences should be debt, not deferred income, and the company says its 2023 operating cash flow was overstated by $163.0 million. It also found tax misstatements. The company says cash and marketable debt securities are not affected.
XNCRBio-Rad began the plan on February 7, 2025 and expects it to be substantially completed by the end of fiscal 2025. The company also made a binding offer to buy Stilla Technologies.
BIOQ32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance.
QTTBX4 will close its Vienna facility and pause preclinical programs to focus on mavorixafor in chronic neutropenia. It expects annual spending to fall by $30-35 million and believes its funds will last into the first half of 2026.
XFORThe board approved the plan on January 22, 2025. Zentalis expects one-time costs of $7.0 million to $8.0 million and believes its cash will fund operations into late 2027.
ZNTLThe company expects a net loss of about $20.33 million for the year ended September 30, 2024, up from $6.16 million a year earlier.
UPCUnder the January 15, 2025 agreement, Arvinas Operations owes no rent after the termination date if it clears the space by January 21, 2025.
ARVNNeogen filed a late-filing notice on January 10, 2025 for its quarterly report for the quarter ended November 30, 2024. The company expects a $461.4 million goodwill impairment on its Food Safety unit and a net loss of $456.3 million, against a loss of $3.5 million a year earlier.
NEOGIntellia says it is cutting its workforce by about 27% net in 2025 and dropping NTLA-3001 to focus on NTLA-2002 and nex-z. It ended 2024 with approximately $862 million and expects about $8 million in charges, but the release gives no headcount or savings figure.
NTLAAfter its Phase 3 ReThink-ALZ study of simufilam missed its co-primary endpoints, Cassava is cutting 10 employees, or 33% of its staff, at a one-time cost of about $0.4 million. It reported unaudited cash of about $128.6 million at December 31, 2024.
FLNAThe Alzheimer's drug developer expects about $0.4 million in one-time costs. The release gives no efficacy numbers for the two Phase 3 studies, and it still plans to report topline results from the one it is discontinuing.
FLNAThe restructuring focuses the company on CX-2051 and its research collaborations. CytomX expects the changes to extend its cash runway into the second quarter of 2026.
CTMXCitius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed.
CTORCTXRThe sale closed December 30, 2024. Veru expects about $12.5 million in net proceeds after a $4.2 million change of control payment to SWK Funding LLC, which ended a residual royalty agreement.
VERUVeru closed the sale of its FC2 female condom business on December 30, 2024 for $18.0 million in cash. After a $4.2 million change of control payment to SWK Funding and other fees, it estimates about $12.5 million in proceeds.
VERUThe company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027.
EDITA 24-month sublease with Vaxcyte at $99,549.53 per month replaces a lease with original monthly rent of $279,540.80.
IOVAThe company filed a late-filing notice on November 15, 2024. It plans to file the report no later than 5 days after the original due date.
ADTXThe company says recent developments diverted management time and internal resources from its financial review. It expects to file within five days.
NGNEThe company missed the November 14, 2024 due date for its report on the quarter ended September 30, 2024. The notice warns that an ongoing review may identify errors or control deficiencies in its accounting practices.
SCLXThe company found that certain warrants and preferred stock issued before 2023 had not been accounted for properly. It estimated cash of $34.3 million at September 30, 2024.
CLRBA separate exhibit carries an audited balance sheet dated February 6, 2024, the company's inception. The auditor's report on it raises going-concern doubt.
ORKA
aibio